← FDA DRUG APPROVALS

FDA NDA · NDA006403

PRISCOLINE

Sponsor: NOVARTIS

APPLICATION
NDA006403
TYPE
NDA
ORIGINAL APPROVAL
1948-03-17
LATEST ACTION
2002-04-29
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

PRISCOLINEDiscontinued
TOLAZOLINE HYDROCHLORIDE 25MG/ML · INJECTABLE · INJECTION

Approval history

2002-04-29Manufacturing (CMC) · Supplement 21AP
1999-04-29Manufacturing (CMC) · Supplement 20AP
1998-10-28Manufacturing (CMC) · Supplement 19AP
1998-10-16Manufacturing (CMC) · Supplement 18AP
1995-11-27Manufacturing (CMC) · Supplement 17AP
1994-12-08Manufacturing (CMC) · Supplement 16AP
1991-10-29Manufacturing (CMC) · Supplement 15AP
1990-01-31Manufacturing (CMC) · Supplement 14AP
1987-11-10Manufacturing (CMC) · Supplement 13AP
1987-11-10Manufacturing (CMC) · Supplement 11AP
1986-10-07Manufacturing (CMC) · Supplement 12AP
1985-02-22Efficacy · Supplement 8AP
1948-03-17OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →